Gilead Sciences, Inc. [NASDAQ: GILD] slipped around -0.43 points on Monday, while shares priced at $73.26 at the close of the session, down -0.58%. The company report on March 18, 2024 at 7:29 PM that Center for Disease Analysis Foundation Announces First Round of Grantees for the CDAF-Relink Grant.
The Center for Disease Analysis Foundation (CDA Foundation) is thrilled to announce the first-round recipients of the CDAF-Relink grant to connect Hepatitis B and C infected individuals in the United States back to care. The program is funded by an eight-million-dollar grant from Gilead Sciences (Nasdaq: GILD) as part of Gilead’s Relink grant program. In this first round, CDA Foundation distributed a total of 2.1 million dollars to the following 14 grantees:.
Compared to the average trading volume of 7.21M shares, GILD reached a trading volume of 5895755 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Gilead Sciences, Inc. [GILD]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for GILD shares is $86.07 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on GILD stock is a recommendation set at 2.28. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Truist have made an estimate for Gilead Sciences, Inc. shares, keeping their opinion on the stock as Hold, with their previous recommendation back on February 22, 2024. While these analysts kept the previous recommendation, Deutsche Bank raised their target price to Hold. The new note on the price target was released on November 09, 2023, representing the official price target for Gilead Sciences, Inc. stock. Previously, the target price had yet another raise from $88 to $95, while BofA Securities kept a Buy rating on GILD stock.
The Average True Range (ATR) for Gilead Sciences, Inc. is set at 1.30, with the Price to Sales ratio for GILD stock in the period of the last 12 months amounting to 3.37. The Price to Book ratio for the last quarter was 4.00, with the Price to Cash per share for the same quarter was set at 6.70. Price to Free Cash Flow for GILD in the course of the last twelve months was 12.30 with Quick ratio for the last quarter at 1.27.
How has GILD stock performed recently?
Gilead Sciences, Inc. [GILD] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -2.73. With this latest performance, GILD shares dropped by -0.15% in over the last four-week period, additionally sinking by -3.18% over the last 6 months – not to mention a drop of -8.25% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for GILD stock in for the last two-week period is set at 43.37, with the RSI for the last a single of trading hit 43.04, and the three-weeks RSI is set at 43.28 for Gilead Sciences, Inc. [GILD]. The present Moving Average for the last 50 days of trading for this stock 77.10, while it was recorded at 74.44 for the last single week of trading, and 77.40 for the last 200 days.
Gilead Sciences, Inc. [GILD]: Deeper insight into the fundamentals
Gilead Sciences, Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.27 and a Current Ratio set at 1.43.
Earnings analysis for Gilead Sciences, Inc. [GILD]
With the latest financial reports released by the company, Gilead Sciences, Inc. posted 1.37/share EPS, while the average EPS was predicted by analysts to be reported at 1.54/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -11.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for GILD. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Gilead Sciences, Inc. go to 5.12%.
Insider trade positions for Gilead Sciences, Inc. [GILD]
The top three institutional holders of GILD stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2815%. BLACKROCK INC., holding 1.03 billion shares of the stock with an approximate value of $176.59 billion in GILD stocks shares; and BERKSHIRE HATHAWAY INC, currently with $156.75 billion in GILD stock with ownership which is approximately 5.8325%.
